ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
ARAVIVE, INC (ARAV) EV/Sales
As of 7 February 2024, ARAVIVE, INC (ARAV) trades at a EV/Sales of −0.4×. Over the past ten years it has ranged from −4.9× (June 2022) to 12.8× (July 2023); the current reading is higher than 10% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −0.3× | — |
| FY2021 | −1.2× | — |
| FY2020 | 3.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | 0.5× | (93.86%) |
| Jun 2023 | 8.7× | (30.27%) |
| Mar 2023 | 12.5× | — |
| Dec 2022 | −0.3× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VIVS VivoSim Labs, Inc. compare | −7.4× |
| ONCO Onconetix, Inc. compare | −7.3× |
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| ARAV ARAVIVE, INC | −0.4× |
| APVO Aptevo Therapeutics Inc. compare | −0.3× |
| GRI GRI Bio, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)